Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine in panic disorder.

F R Schneier1, M R Liebowitz, S O Davies

  • 1New York State Psychiatric Institute, Columbia University, New York.

Journal of Clinical Psychopharmacology
|April 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RDoC is adverse to scientific creativity.

Acta psychiatrica Scandinavica·2016
Same author

Commentary on 'Psychology and pharmacology in the treatment of anxiety disorders: co-operation or confrontation?'.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss.

Psychological medicine·2010
Same author

Atypical depression: current status and relevance to melancholia.

Acta psychiatrica Scandinavica. Supplementum·2007
Same author

Respiratory variability in panic disorder.

Depression and anxiety·2001
Same author

Acute panic inventory symptoms during CO(2) inhalation and room-air hyperventilation among panic disorder patients and normal controls.

Depression and anxiety·2001
Same journal

Aripiprazole Withdrawal-Associated Restless Legs Syndrome During Clozapine Treatment in an Adolescent With Schizoaffective Disorder: A Case Report.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Article Selected to Receive the Mitchell B. Balter Award for Publications in 2025.

Journal of clinical psychopharmacology·2026
Same journal

Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Serotonin Syndrome Associated With Polypharmacy in an Elderly Patient With Dementia and Parkinson Disease.

Journal of clinical psychopharmacology·2026
See all related articles

Low-dose fluoxetine effectively treats panic disorder. Starting with 5 mg/day improved 76% of patients, increasing treatment acceptance and benefits for panic disorder with or without agoraphobia.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Psychology

Background:

  • Panic disorder is a debilitating condition often treated with selective serotonin reuptake inhibitors (SSRIs).
  • Fluoxetine, a widely used SSRI, has shown efficacy in treating panic disorder.
  • Optimizing fluoxetine's tolerability is crucial for patient adherence and treatment success.

Observation:

  • This open-label study evaluated fluoxetine treatment in 25 patients diagnosed with panic disorder with or without agoraphobia.
  • Treatment involved a low initial dose of 5 mg/day to mitigate adverse effects.
  • Patients were observed for up to 12 months.

Findings:

  • Nineteen out of 25 patients (76%) demonstrated moderate to marked improvement in panic attacks.
  • Only 4 patients (16%) discontinued treatment due to adverse effects.

Related Experiment Videos

  • The low-dose initiation strategy was well-tolerated by the majority of participants.

    • Implications:

    • Initiating fluoxetine treatment for panic disorder at low doses (5 mg/day) enhances patient acceptability.
    • This approach may enable more patients with panic disorder to benefit from fluoxetine therapy.
    • Low-dose fluoxetine represents a viable strategy for improving panic disorder management.